NFE2L2 and neoplasm: Conversely, persistent or constitutive activation—often due to mutations in KEAP1 or Nuclear factor erythroid 2-like 2 (NFE2L2) which encodes NRF2, or metabolic rewiring—confers a tumor-promoting phenotype, enhancing survival, proliferation, and treatment resistance in established cancers [4,5].